Introduction {#s1}
============

Type 2 diabetes mellitus (T2DM) is an expanding global health problem ([@B1]). There are 347 million people worldwide with diabetes, and more than 80% of diabetes deaths occur in low- and middle-income countries. According to statistics, 9.7% of people in China have type 2 diabetes, which not only threatens health, but also reduces quality of life and life expectancy ([@B2]). The onset of T2DM is multifactorial due to the interplay of common variation in multiple genes and environmental factors, but the exact pathogenesis of T2DM remains unclear ([@B3]).

Before type 2 diabetes occurs, glucose control is altered, which is reflected by higher fasting glucose and/or higher post-prandial glucose. This phenomenon is called impaired glucose regulation (IGR) and IGR is regarded as pre-diabetic state that includes impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) ([@B4]). High glucose may cause an adverse effect on insulin sensitivity and secretion, further developing into glucotoxicity ([@B5]). Previous studies have shown that 5--10% IGT individuals develop diabetes each year, although some revert to normal glucose tolerance ([@B6]).

Recent developments in the understanding of T2DM have been heightened by the potential relevance of dysfunctional zinc signaling in this disease. Zinc is an important element for insulin storage and secretion ([@B7]). Zinc transporter 8 (ZnT-8), a member of the zinc transporter family, has been shown to bind with insulin in beta cells to form a solid hexamer, which is stored in secretory vesicles ([@B8]). Zinc transporter solute carrier family 30 member 8 (*SLC30A8*) is located on chromosome 8q24.11. It encodes ZnT-8, which is highly expressed in pancreatic islets and beta cells. ZnT-8 transports zinc from the cytoplasm into insulin secretary vesicles. Some studies have shown that the polymorphisms of *SLC30A8* are associated with β-cell function and insulin release *in vivo* ([@B9], [@B10]) and *in vitro* ([@B11]).

The non-synonymous single-nucleotide polymorphism, rs13266634, of *SLC30A8* causes an amino acid change from arginine (R) to tryptophan (W) at position 325 (Arg325Trp). The association of rs13266634 polymorphism in IGR and T2DM has been demonstrated in different ethnic groups via GWAS ([@B12]--[@B16]). The major C allele of the rs13266634 polymorphism is strongly associated with Chinese IGR and T2DM patients. However, the results are contradictory, and not all variants associated with type 2 diabetes are related with impaired glucose. These different results might be due to racial and regional differences, and they may be due to the limitation of the number of patients per study. To reduce the influence of diverse genetic backgrounds, a meta-analysis based on the Chinese population was performed to assess the relationship between rs13266634 polymorphism and IGR/T2DM.

Materials and methods {#s2}
=====================

Search strategy
---------------

We searched the PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Wan Fang and CBMD databases for articles published prior to January 2018. The searching languages contained both English and Chinese, and only published studies were considered. The search strategy was based on combination of "*SLC30A8*," "rs13266634," "polymorphism^\*^," "variant^\*^," "genotype^\*^," "diabetes," "T2DM," "impaired glucose regulation," "IGR," "Chinese," and "China." References of retrieved articles were also screened and selected.

Inclusion and exclusion criteria
--------------------------------

Studies included in the meta-analysis met all of the following criteria: (1) the association between *SLC30A8* rs13266634 polymorphism and T2DM/IGR; ([@B2]) Chinese population; ([@B3]) sufficient data about allele or genotype frequency in cases and controls; ([@B4]) providing the odds ratio (OR) and its 95% confidence interval (95%CI) of the polymorphism; and ([@B5]) and clear diagnosis of T2DM/IGR. Studies were excluded if genotype frequency data in the controls demonstrated departure from Hardy-Weinberg equilibrium (HWE). When the same data were included in more than one publication, only the most relevant articles with the largest data set were included in the final analysis.

Data extraction
---------------

The following data elements from each study were extracted: name of first author, year of publication, region of the study population, ethnicity of Chinese population, source of control, genotype method, diagnostic criteria, risk allele (C allele) frequency, number of cases and controls, mean (or median) body mass index (BMI), percentage of men in cases and controls, and mean (or median) age. Data were independently extracted by two investigators who reached a consensus on all of the items. If there was a lack of genotype information, we contacted the corresponding author to obtain required data.

Risk of bias assessment
-----------------------

The quality of studies was also independently assessed by two reviewers (DF and ZFF) based on a risk of bias assessment for genetic association study which was modified on the basis of both traditional epidemiologic considerations and genetic issues that were developed by Thakkinstian et al. ([@B17], [@B18]). The score was divided into five domains, including information bias, confounding bias, selective reporting of outcomes, population stratification, and Hardy-Weinberg equilibrium (HWE) in the control group. Quality scores of each study ranged from 0 (lowest) to 15 (highest). Studies with scores ≤10 were categorized into low quality, while those with scores \>10 were considered as high quality. Disagreement between the two reviewers was solved by a senior reviewer (JCX).

Statistical analysis
--------------------

We used Stata 11.0 (College Station, TX, USA) for all statistical analyses. The HWE was examined in control groups by Fisher\'s Exact Test. If the study was found not to be in HWE with *P*-value \<0.05, it was considered to be disequilibrium. Both per-allele and per-genotype approaches were performed to estimate the effect of the rs13266634 polymorphism on the risk of T2DM or IGR.

Per-allele analysis: The risk allele C frequency for rs13266634 was estimated for each study by reported data, and the overall prevalence and 95% confidence interval (95%CI) were estimated. Odds ratios (ORs), as well as 95%CI, were also estimated.

Per-genotype analysis: The genotype effect was also calculated if the genotype data could be extracted from the study. Three odds ratios were estimated: CC vs. TT (OR1), CT vs. TT (OR2), and CC vs. CT (OR3). If the main effect of the genotype was statistically significant, further comparisons of OR1, OR2 and OR3 were explored. These pairwise differences were used to indicate the most appropriate genetic model as follows: (1). If OR1 = OR3≠1 and OR2 = 1, a recessive model was suggested. (2). If OR1 = OR2 ≠ 1 and OR3 = 1, then a dominant model was suggested. (3). If OR2 = 1/OR3 ≠ 1 and OR1 = 1, then a complete overdominant model is suggested. (4). If OR1 \> OR2 \> 1 and OR1 \> OR3 \> 1 (or OR1 \< OR2 \< 1 and OR1 \< OR3 \< 1), a co-dominant model was suggested.

The estimation of the allele or genotype effect on T2DM was calculated by an OR and 95%CI. The *Z*-test was used to determine the statistical significance of the pooled OR, and its *P*-value was used to determine if the overall SNP effect was significant (α = 0.05). The Q test based on a Chi-square analysis was used to assess the existence of heterogeneity. *p* = 0.01 was selected as the boundary value of the judgment to minimize type 2 errors ([@B19]). The pooled OR with 95% CI was calculated using the random-effects model based on the DerSimonian and Laird method ([@B20]). The random-effects model was chosen a priori because it is considered as more conservative than the fixed-effects model, as it accounts for both within- and between-study heterogeneity ([@B21]). In addition, the degree of heterogeneity was quantified using *I*^2^ (*I*^2^ \< 25%, no heterogeneity; 25% \< *I*^2^ \< 50%, moderate heterogeneity; 50% \< *I*^2^ \< 75%, large heterogeneity; and *I*^2^ \> 75% extreme heterogeneity) ([@B22]). A random-effects model was selected if *I*^2^ was \>50%. The cause of heterogeneity was explored by fitting covariates (i.e., age, body mass index, percentage of men, source of control, genotype method, or sample size) in a meta-regression if these data were available. A subgroup analysis was performed according to publication year, source of control, sample size, and quality scores.

A sensitive analysis with a single study being removed each time was performed to reflect the influence of the individual data set on the pooled OR. Publication bias was evaluated using Egger\'s linear regression asymmetry test and visual inspection of funnel plots, and the influence of potential publication bias on results was explored by using the Duval and Tweedie trim-and-fill procedure ([@B23], [@B24]). *P* \< 0.05 was considered statistically significant in all analyses, except for the Egger test (*p* \< 0.10) because of the low power of the test.

Trial sequential analysis
-------------------------

Meta-analyses might result in type-I errors owing to an increased risk of random error when fewer patients are involved, and due to continuous significance testing when a cumulative meta-analysis is updated with new studies ([@B25], [@B26]). Therefore, to assess the risks of random errors, trial sequential analysis (TSA) was performed using Stata 11.0 software package (metacumbounds command), which combines information size estimation for meta-analysis (cumulated sample size of included trials) with an adjusted threshold for statistical significance in the cumulative meta-analysis. TSA was conducted with the intention to maintain an overall 5% risk of a type I error and a power of 80%. For the calculation of the required information size, an intervention effect of a 20% relative risk reduction (RRR) was anticipated using the control event proportion calculated from the actual meta-analyses.

Results {#s3}
=======

Studies included in the meta-analysis
-------------------------------------

A total of 381 articles were retrieved by literature search (Figure [1](#F1){ref-type="fig"}). After removal of 124 duplicates, 257 studies were screened for title and abstract as well as full text with 38 articles determined to be eligible. The following 10 studies were further excluded: five duplicate publications ([@B27]--[@B31]); four articles ([@B32]--[@B35]) with controls not in HWE; and one study ([@B36]) that reported data in combination with T2DM and IGR cases. Finally, 28 case-control studies with 25,912 cases and 26,975 controls were associated with T2DM, and five studies with 4,627 cases and 6,166 controls were associated with IGR. The characteristics and genotype distribution of included studies are listed in Table [1](#T1){ref-type="table"}; Supplementary Table [1](#SM1){ref-type="supplementary-material"}.

![Flow chart for the selection of included studies.](fendo-09-00564-g0001){#F1}

###### 

The characteristics of the included studies in the meta-analysis.

  **First author \[ref\]**   **Publication year**   **Region**         **Source of control**   **Genotype method**                          **Diagnosis criteria**   **Sample size**   **Men (%)**   **Mean age (year)**   **BMI (kg/m**^**2**^**)**   **Quality score**                              
  -------------------------- ---------------------- ------------------ ----------------------- -------------------------------------------- ------------------------ ----------------- ------------- --------------------- --------------------------- ------------------- ---------- ------- ------- ----
  **T2DM**                                                                                                                                                                                                                                                                                            
  Wang ([@B37])              2008                   Chongqing          Hospital                PCR-RFLP                                     WHO                      454               311           54.6                  59.2                        55                  50         24.9    23.4    8
  Wu ([@B38])                2008                   Beijing/shanghai   Population              SNPstream[^\*^](#TN1){ref-type="table-fn"}   WHO                      424               1,908         48.8                  41.5                        59.7                58.4       25.1    23.5    12
  Xiang ([@B39])             2008                   Shanghai           Population              Mass array                                   WHO                      521               721           40.3                  37.4                        62.6                59.7       26.3    24.1    13
  Hu ([@B40])                2009                   Shanghai           Population              SNP-array                                    WHO                      1,849             1,785         52.46                 41.23                       61.21               57.39      24.04   23.57   11
  Han ([@B41])               2010                   Beijing            Population              SNapShot                                     WHO                      992               993           52.7                  34.2                        56                  58         25.0    25.0    11
  Lin ([@B42])               2010                   Chengdu            Hospital                SNapShot                                     WHO                      1,529             1,439         47.8                  50                          60.2                58.1       23.9    23.5    10
  Shu ([@B43])               2010                   Shanghai           Population              SNP-array                                    SC                       1,019             1,710         0                     0                           51.7                48.7       26.5    23.1    14
  Tan ([@B44])               2010                   Singapore          Population              Mass array                                   WHO                      1,541             2,196         NA                    NA                          NA                  NA         NA      NA      12
  Xu ([@B45]) CCS            2010                   Shanghai           Population              SNapShot                                     SC                       1,825             2,200         43.9                  38.4                        63.3                59.3       26.3    24.3    12
  Li ([@B46])                2011                   Inner Mongolia     Hospital                AS-PCR                                       SC                       125               97            54.4                  55.67                       57.90               52.55      25.72   23.99   7
  Wang ([@B47])              2011                   Hengyang           Hospital                PCR-RFLP                                     WHO                      236               218           51.3                  50                          57.4                54.1       23.8    22.4    6
  Fu ([@B48])                2012                   Chongqing          Hospital                SNapShot                                     WHO                      727               650           48                    46.2                        59.85               60.39      23.92   23.99   9
  Zheng ([@B49])             2012                   Chongqing          Population              Mass array                                   WHO                      227               152           61.67                 38.82                       54.05               52.80      25.27   23.67   7
  Chen ([@B50])              2013                   Ningde             Population              SNP-assay                                    WHO                      443               1,119         0                     0                           NA                  NA         NA      NA      12
  Tam ([@B51])               2013                   Hong Kong          Population              Mass array                                   WHO                      5,882             2,569         45.5                  47.5                        56.8                41.8       25.1    21.8    12
  Chang ([@B52])             2014                   TaiWan             Hospital + Population   SNPstream[^\*^](#TN1){ref-type="table-fn"}   ADA                      1,502             1,518         51.26                 50.86                       60.42               55.83      25.45   24.27   9
  Chen ([@B53])              2014                   Gansu              Hospital                PCR-RFLP                                     WHO                      116               80            51.72                 51.25                       50.99               46.99      24.7    24.4    5
  Jin ([@B54])               2014                   Yanbian            Hospital                SNaPshot                                     WHO                      313               178           52.2                  39.8                        61.15               49.18      23.86   25.3    6
  Zhang ([@B55])             2014                   Gansu              Hospital                PCR-RFLP                                     WHO                      123               129           56.91                 57.36                       49.76               46.98      NA      NA      6
  Chen ([@B56])              2015                   ChangChun          Hospital                LDR                                          WHO                      113               107           NA                    NA                          52.26               NA         25.59   NA      6
  Kamila ([@B57])            2015                   Xinjiang           Hospital                PCR-RFLP                                     WHO                      116               126           55.17                 49.21                       54.65               54.44      26.75   26.11   6
  Liu ([@B58])               2015                   Jinzhou            Hospital                PCR-HRM                                      WHO                      136               145           47.8                  47.6                        51.42               52.63      NA      NA      6
  Qian ([@B59])              2015                   Jiangsu            Population              Mass array                                   ADA                      2,925             3,281         37.5                  37.6                        58.21               56.57^a^   25.05   22.12   13
  Su ([@B60])                2015                   Xinjiang           Hospital                Mass array                                   ADA                      1,000             1,010         62.70                 62.87                       51.14               50.33      NA      NA      10
  Zhang ([@B61])             2015                   Gansu              Hospital                PCR-RFLP                                     WHO                      138               135           52.17                 55.56                       56.99               54.76      24.66   23.82   6
  Zhang ([@B61])             2015                   Gansu              Hospital                PCR-RFLP                                     WHO                      125               127           51.20                 62.20                       53.55               54.57      24.69   24.05   6
  Zhao ([@B62])              2015                   Nanjing            Population              Mass array                                   WHO                      1,737             1,950         42.95                 31.33                       64.31               57.69      25.2    23.59   12
  Zou ([@B63])               2016                   Jilin              Hospital                PCR sequencing                               WHO                      214               243           60.54                 48.97                       41.6                22.5       25.6    21.5    6
  **IGR**                                                                                                                                                                                                                                                                                             
  Wu ([@B38])                2008                   Beijing/shanghai   Population              SNPstream[^\*^](#TN1){ref-type="table-fn"}   SC                       878               1,908         48.4                  41.5                        58.6                58.4       25.2    23.5    12
  Xiang ([@B39])             2008                   Shanghai           Population              Mass array                                   SC                       375               721           37.3                  37.4                        63.7                59.7       25.7    24.1    13
  Xu ([@B45])                2010                   Shanghai           Hospital                SNapShot                                     SC                       1,487             2,200         40.0                  38.4                        61.0                59.3       25.5    24.3    12
  Wang ([@B47])              2011                   Hengyang           Hospital                PCR-RFLP                                     SC                       120               218           47.5                  50                          53.9                54.1       23.1    22.4    6
  Chen ([@B50])              2013                   Ningde             Population              SNP-Assay                                    SC                       1,767             1,119         0                     0                           NA                  NA         NA      NA      12

*Genome Lab SNPstream genotyping system*.

*ADA, American Diabetes Association; IGR, impaired fasting glucose; LDR, ligase detection reaction; NA, not available; PCR-HRM, polymerase chain reaction--high resolution melt; PCR-RFLP, cleaved amplification polymorphism sequence-tagged sites; SC, some diagnostic criteria but not clearly describe according to WHO criteria; SNP, single nucleotide polymorphisms; T2DM, type 2 diabetes mellitus; WHO, World Health Organization*.

Association between SLC30A8 rs13266634 polymorphism and T2DM risk
-----------------------------------------------------------------

Per-allele analysis: The pooled allele frequency was calculated in both case and control groups. The risk allele C frequency was 60.6% (95%CI: 59.2--62.0%) in the T2DM group with high heterogeneity (*I*^2^ = 88.8%, *p* \< 0.001) and 54.8% (95%CI: 53.2--56.4%) in the control group (*I*^2^ = 91.5%, *p* \< 0.001). The odds ratio (C vs. T) was largely heterogenous (χ^2^ = 34.24, *p* = 0.008, *I*^2^ = 50.35) with a pooled odds ratio of 1.23 (95%CI: 1.17--1.28), and the overall SNP effect estimated by the random effect model was significant (*p* \< 0.001; Table [2](#T2){ref-type="table"}; Figure [2](#F2){ref-type="fig"}). These results suggested that individuals carrying the major C allele had 23% increased risk of developing T2DM than those carrying the minor T allele.

###### 

Total and stratified analyses of SLC30A8 rs13266634 polymorphism and T2DM risk among Chinese.

  **Summary**                                             ***N***   **Cases/Controls**   **C vs. T**                  **CC vs. TT**   **CT vs. TT**   **CC vs. CT**                                                                                                                                  
  ------------------------------------------------------- --------- -------------------- ---------------------------- --------------- --------------- ---------------------------- ------------- ------ ---------------------------- ------------- ------ ---------------------------- ------------- ------
  Total                                                   28        25,912/26,975        1.23 (1.17, 1.28)            \<**0.001**     55.5            1.51 (1.38, 1.65)            \<**0.001**   53.9   1.23 (1.15, 1.30)            \<**0.001**   19.4   1.19 (1.14, 1.25)            \<**0.001**   12.2
  **PUBLICATION YEAR**                                                                                                                                                                                                                                                                               
  \< 2014                                                 15        17,360/17,950        1.21 (1.15, 1.27)            \<**0.001**     53.9            1.47 (1.32, 1.62)            \<**0.001**   53.2   1.23 (1.14, 1.33)            \<**0.001**   31.6   1.19 (1.13, 1.25)            \<**0.001**   0.0
  ≥2014                                                   13        8,552/9,025          1.28 (1.17, 1.40)            \<**0.001**     60.3            1.65 (1.38, 1.97)            \<**0.001**   58.1   1.22 (1.11, 1.34)            \<**0.001**   7.7    1.25 (1.12, 1.40)            \<**0.001**   44.1
  **SOURCE OF CONTROL**[^a^](#TN2){ref-type="table-fn"}                                                                                                                                                                                                                                              
  Population                                              12        18,951/20,466        1.17 (1.12, 1.22)            \<**0.001**     42.8            1.36 (1.26, 1.47)            \<**0.001**   36.9   1.16 (1.10, 1.23)            \<**0.001**   0.0    1.18 (1.12, 1.23)            \<**0.001**   0.0
  Hospital                                                15        5,406/4,991          1.35 (1.23, 1.49)            \<**0.001**     53.8            1.88 (1.56, 2.27)            \<**0.001**   47.1   1.45 (1.25, 1.68)            \<**0.001**   25.0   1.25 (1.11, 1.41)            \<**0.001**   32.2
  **SAMPLE SIZE**                                                                                                                                                                                                                                                                                    
  \< 1,000                                                13        2,431/2,044          1.40 (1.22, 1.60)            \<**0.001**     58.4            1.99 (1.51, 2.63)            \<**0.001**   56.4   1.48 (1.20, 1.83)            \<**0.001**   35.8   1.33 (1.11, 1.58)            \<**0.001**   35.4
  ≥1,000                                                  15        23,481/24,931        1.19 (1.15, 1.23)            \<**0.001**     32.4            1.41 (1.32, 1.51)            \<**0.001**   29.2   1.19 (1.13, 1.25)            \<**0.001**   0.0    1.18 (1.13, 1.23)            \<**0.001**   0.0
  **SCORE**                                                                                                                                                                                                                                                                                          
  \< 10                                                   15        4,659/4,212          1.35 (1.22, 1.51)            \<**0.001**     58.6            1.87 (1.51, 2.31)            \<**0.001**   55.0   1.42 (1.22, 1.67)            \<**0.001**   30.1   1.28 (1.12, 1.46)            \<**0.001**   34.4
  ≥10                                                     13        21,253/22,763        1.18 (1.14, 1.22)            \<**0.001**     27.1            1.39 (1.30, 1.49)            \<**0.001**   24.5   1.18 (1.11, 1.24)            \<**0.001**   0.0    1.18 (1.13, 1.23)            \<**0.001**   0.0
  **SENSITIVITY ANALYSIS**                                                                                                                                                                                                                                                                           
  Minimal                                                 27        -/-                  1.21 (1.16, 1.26) ([@B47])   \<**0.001**     47.2            1.48 (1.36, 1.60) ([@B47])   \<**0.001**   45.9   1.20 (1.15, 1.26) ([@B47])   \<**0.001**   0.0    1.18 (1.13, 1.24) ([@B50])   \<**0.001**   5.5
  Maximal                                                 27        -/-                  1.24 (1.18, 1.29) ([@B62])   \<**0.001**     54.3            1.54 (1.40, 1.68) ([@B62])   \<**0.001**   52.8   1.24 (1.16, 1.32) ([@B59])   \<**0.001**   17.4   1.20 (1.15, 1.26) ([@B62])   \<**0.001**   11.0

*One study with mixed of hospital and population source of control ([@B52])*.

*OR, odds ratio; T2DM, type 2 diabetes mellitus; significant P-values in bold*.

![Forest plot of association between SLC30A8 rs13266634 polymorphism and T2DM risk in C vs. T model.](fendo-09-00564-g0002){#F2}

The pooled OR and 95% CI for the association between the rs13266634 polymorphism and T2DM risk was 1.51 (1.38, 1.65; *p* \< 0.001) with large between-study heterogeneity (*I*^2^ = 53.9%) for CC vs. TT, 1.23 (1.15, 1.30; *p* \< 0.001) with small heterogeneity (*I*^2^ = 19.4%) for CT vs. TT, and 1.19 (1.14, 1.25; *p* \< 0.001) with small heterogeneity (*I*^2^ = 12.2%) for CC vs. CT, which suggests a co-dominant model (CC vs. CT vs. TT) for the putative susceptibility allele C with T2DM (Table [2](#T2){ref-type="table"}).

Stratified analysis indicated significantly stronger associations among controls coming from hospitals, among studies with lower number of participants, and among studies with lower quality for C vs. T (OR for controls from hospitals vs. populations: 1.35 vs. 1.17, *p* interaction = 0.008; OR for studies with sample size \< 1,000 vs. ≥1,000: 1.40 vs. 1.19, *p* interaction = 0.023; OR for studies with quality score \< 10 vs. ≥10: 1.35 vs. 1.18, *p* interaction = 0.018), for CC vs. TT (OR for controls from hospitals vs. populations: 1.88 vs. 1.36, *p* interaction = 0.002; OR for studies with sample size \< 1,000 vs. ≥1,000: 1.51 vs. 1.32, *p* interaction = 0.018; OR for studies with quality score \< 10 vs. ≥10: 1.51 vs. 1.30, *p* interaction = 0.009), and for CC vs. CT (OR for controls from hospitals vs. populations: 1.45 vs. 1.16, *p* interaction = 0.006; OR for studies with sample size \< 1,000 vs. ≥1,000: 1.48 vs. 1.19, *p* interaction = 0.049; OR for studies with quality score \< 10 vs. ≥10: 1.42 vs. 1.18, *p* interaction = 0.029; Table [2](#T2){ref-type="table"}). Meta-regression further confirmed the effect of the source of control and quality score, but not total sample size, for C vs. T, CC vs. TT, and CC vs. CT comparisons (Supplementary Table [2](#SM2){ref-type="supplementary-material"}). Influence analyses by removing one study each time revealed that the pooled ORs remained significant for all comparisons (Table [2](#T2){ref-type="table"}).

Egger\'s test showed significant evidence of publication bias (C vs. T: *p* = 0.014; CC vs. TT: *p* = 0.008; CC vs. TT: *p* = 0.015; CC vs. TT: *p* = 0.090), and the funnel plots for all comparisons were asymmetric. However, after imputing 6, 6, 4, and 1 missing studies for C vs. T, CC vs. TT, CC vs. TT, and CC vs. TT, respectively, by using the trim-and-fill method, the recalculated pooled ORs were not substantially different from the initial (Figure [3](#F3){ref-type="fig"}; Supplementary Table [3](#SM3){ref-type="supplementary-material"}).

![Trill and fill plot of associations between SLC30A8 rs13266634 polymorphism and T2DM risk in C vs. T model.](fendo-09-00564-g0003){#F3}

Trial sequential analyses: Because both the monitoring boundaries and information size had a cumulative Z-statistic \>1.96, the evidence confirmed a risk effect of C allele on prevalence of T2DM (Figure [4](#F4){ref-type="fig"}).

![Trial sequential analysis for association between SLC30A8 rs13266634 polymorphism and T2DM risk in C vs. T model.](fendo-09-00564-g0004){#F4}

Association between SLC30A8 rs13266634 polymorphism and IGR risk
----------------------------------------------------------------

The pooled frequency of the major C allele was estimated to be 57.2% (95%CI: 55.8--58.7%) with moderate heterogeneity (*I*^2^ = 43.0%) in IGR group, and it was 54.0% (95%CI: 50.5--57.5%; *I*^2^ = 90.0%) in the control group. The pooled OR of C vs. T was 1.13 (95% CI: 0.98--1.30; *p* = 0.082) with significant between-study heterogeneity (*I*^2^ = 81.0%; Figure [5](#F5){ref-type="fig"}). Egger\'s test (*p* = 0.257) suggested that there was no publication bias.

![Forest plot of association between SLC30A8 rs13266634 polymorphism and IGR risk in C vs. T model.](fendo-09-00564-g0005){#F5}

Per-genotype analysis also indicated that there were no significant associations between rs13266634 polymorphism and IGR risk (OR1: 1.27, 0.96--1.68, *p* = 0.089; OR2: 1.13, 0.95--1.34, *p* = 0.169; OR3: 1.08, 0.95--1.21, *p* = 0.243; Table [2](#T2){ref-type="table"}).

Trial sequential analyses: because the cumulative z-curve fluctuated around both the traditional boundary and the trial sequential monitoring boundary, the evidence was not conclusive for the outcome (Figure [6](#F6){ref-type="fig"}).

![Trial sequential analysis for association between SLC30A8 rs13266634 polymorphism and IGR risk in C vs. T model.](fendo-09-00564-g0006){#F6}

Discussion {#s4}
==========

A systematic review and meta-analysis was performed to investigate the association between *SLC30A8* rs13266634 and T2DM and IGR in a Chinese population, including 25,912 cases and 26,975 controls from 28 studies associated with T2DM, as well as 4,627 cases and 6,166 controls from five studies associated with IGR. The results suggested a significant association between the rs13266634 polymorphism and T2DM, which is consistent with previous results ([@B64]) but different from a study in Arab ethnicity ([@B65]). This association was also reported as significant in an African population under the allelic model, but neither under the codominant or recessive model ([@B66]). The expression differences of the same polymorphism between different ethnic groups might be caused by different genetic backgrounds and various environmental factors ([@B67]). In the present meta-analysis, individuals who carried the C allele had 23% increased risk of developing T2DM relative to those carrying the T allele in the Chinese ethnicity. These results were consistent but slightly higher than the GWAS database, which reports that people carrying the C allele may have an increased 18% risk of developing T2DM in a Finnish population ([@B13]). The genotype effect calculation showed that people with homozygous and heterozygous genotypes had 51 and 23%, respectively, higher risk of developing T2DM. The result agreed with GWAS research showing that homozygous and heterozygous individuals had 53 and 18%, respectively, higher risk of having T2DM ([@B15]). The frequency of risk allele C was 54.8% in the healthy Chinese group, which was lower than that in French (69.9%), Austrian (74.03%), and African American populations (91.59%) ([@B15], [@B68]). There were five case-control studies that described the association between the rs13266634 polymorphism and IGR, which included 4,627 cases and 6,166 controls. The evaluation indicated that the rs13266634 polymorphism was not associated with IGR in the Chinese population (OR = 1.13, 95%CI = 0.98--1.30, *p* = 0.082). It should be noted that this result was not consistent with the study in Europeans ([@B13]). These discrepancies may be attributed to the difference between genetic backgrounds of population substructure and sample size.

Zinc is necessary in β-cells for insulin crystallization in hexamers. Zinc is co-secreted with insulin, and participates in the regulation of β-cell mass by antioxidant actions ([@B69], [@B70]). Zinc plays an important role in β-cell function and insulin homeostasis. The ZnT8 transporter is primarily expressed in β-cells and co-localizes with insulin-containing secretory granules ([@B71]), and the alteration of ZnT8 expression may modulate insulin secretion. A previously study suggested that the *SLC30A8* rs13266634 polymorphism impairs ZnT8 expression in islets by disrupting the protein kinase A and protein kinase C recognition motif (R-X-S/T) in the ZnT8 molecule ([@B7]). Recent research has shown that the *SLC30A8* variant may affect glucose via modulating total zinc intake ([@B72]). These studies provided information for the underlying mechanisms of impaired glucose regulation and T2DM, potentially aiding the development of novel and individualized medical therapies. However, neither environmental triggers nor genetics alone can explain type 2 diabetes as a multifactorial disease. Thus, a close interaction between genetics and environment is presumed. Hence, it is still too early to draw such a conclusion until more functional research and larger population-based validation tests are performed.

Stratified analysis of control source, sample size, and quality score for T2DM showed that a significantly higher risk of T2DM was found in studies conducted using control source from hospitals with sample size \<1,000 and with quality score \<10. These results suggested that studies using controls from hospitals, small sample size, and low quality tend to overestimate the overall effect. However, subgroup analyses revealed that the risk effect of C allele from studies with controls from population, large sample size, and higher quality persisted. In addition, after excluding studies with controls from hospitals, small sample size, and especially low quality studies, the significant heterogeneity for allele comparison was markedly reduced from 55.5 to 27.1--42.8% for the CC vs. TT comparison as well as from 53.9 to 24.5--36.9% for the C vs. T comparison. The effect of quality score was the most evident because calculation of quality scores considered both the source of controls and sample size.

To the best of our knowledge, this is one of the most comprehensive meta-analysis for the association of *SLC30A8* rs13266634 polymorphism in IGR and T2DM risk in a Chinese population. A detailed search strategy was used in multiple databases, which was applied to include as many eligible studies as possible. Data extraction was performed in duplicate, and the qualities of included studies were evaluated by similar scale. Previous studies have confirmed the association between *SLC30A8* and T2DM ([@B64], [@B73]), but subgroup analysis was based only on different continents. Thus, it was necessary to perform a meta-analysis in the Chinese population due to its large population base and complicated genetic backgrounds. In addition, TSA was conducted to test if sufficient information size had been reached, minimizing potentially false positive results and providing the basis for further studies. TSA indicated that the cumulative *Z*-curve of the IGR fluctuated around both the traditional boundary and the trial sequential monitoring boundary, suggesting that additional studies are needed for this endpoint.

Limitations
-----------

There were limitations in our study. First, case-control studies may overestimate the effect size of the association, which make the relationship between exposure and outcome less clear. To avoid such bias, the population should be based on a nested case-control study. Second, there were 19 articles with genotype data (19/28), and the estimation of genotype effects on T2DM may not be strong enough. Thus, a more precise association should be explored with sufficient data. These results should be interpreted with caution until further verification of sequencing approaches and larger meta-analysis are performed. Finally, significant publication bias was observed for all comparisons for T2DM. However, after imputing missing studies by using the trim-and-fill method, the recalculated pooled ORs were not substantially changed.

Conclusion {#s5}
==========

The present meta-analysis indicated that the rs13266634 C allele in the *SLC30A8* gene was associated with T2DM risk in the Chinese population. More studies are needed to confirm the association between rs13266634 polymorphism and IGR risk. The current evidence is insufficient to inform clinical decision making or policies until better understanding of the full functional implications is obtained. In addition, comprehensive analyses of gene-gene and gene-environment interactions should also be evaluated in the future.
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